Core Viewpoint - The Hong Kong technology sector experienced a rebound on December 19, with significant gains in biotechnology stocks, particularly benefiting from the recent passage of the 2026 National Defense Authorization Act (2026 NDAA) in the U.S. [1] Group 1: Market Performance - The Hang Seng Biotechnology and Hong Kong Stock Connect Technology Indexes led the gains, with WuXi Biologics rising over 5% and WuXi AppTec increasing more than 4% [1] - Other notable performers included Innovent Biologics and CanSino Biologics, both of which saw increases exceeding 2% [1] Group 2: Regulatory Impact - The new version of the U.S. bioterrorism law did not specifically name any companies, which is seen as a significant positive for Chinese CXO companies, including WuXi AppTec and WuXi Biologics, that have been under pressure from previous regulations [1] Group 3: Investment Opportunities - There are low-positioning opportunities in related ETFs covering Hong Kong CXO leaders, specifically the Hang Seng Pharmaceutical ETF (159892.SZ) and the Hong Kong Stock Connect Technology ETF (159101.SZ) [1]

兴业证券认为，近期创新药板块情绪回落，随着BD持续落地，该行认为当前板块景气度可持续，"创新 +国际化"创新药产业趋势不变，短期调整后创新药板块弹性进一步提升。同时，可继续重点关注基本 面已开始改善的创新药产业链，当前在投融资数据、订单和业绩层面均看到向好趋势。 消息面上，据券商中国日前报道，北京时间12月18日凌晨，参议院官网显示，搭载修订版《生物安全法 案》的美国2026财年国防授权法案（2026NDAA）获通过。新版本生物安全法未具体点名任何一家公 司。有券商研究机构认为，2025年法案进展阶段性落地，行业回归中长期增量逻辑。 智通财经APP获悉，医药股今早明显反弹，CRO、创新药方向居前。截至发稿，凯莱英(06821)涨 6.28%，报77港元；药明生物(02269)涨6.11%，报34.72港元；三生制药(01530)涨5.04%，报26.68港元； 诺诚健华(09969)涨4.25%，报13.74港元。 ...

港股止跌，整个早盘都维持在中轴附近窄幅盘整，大消费和科技小幅收红，互联网和医疗走了和寂寞。 大消费探底回升后震荡上行，截止午盘小涨0.32%。其中李宁都在4.37%，申洲国际上涨2.26%，石药集 团、老铺黄金、药明生物、泡泡玛特等股涨幅均在1%上方；创科实业、小鹏汽车、地平线等股逆势绿 盘。 科技股开盘一直围绕中轴盘整，截止午盘小涨0.14%。其中美团上涨1.21%，京东集团、阿里巴巴、腾 讯控股、中芯国际等股均小幅收涨；比亚迪股份、网易等股逆势小跌。 恒生医疗走了个寂寞，其中石药集团上涨1.9%，药明生物上涨1.68%，百济神州、信达生物、三生制药 等股均小幅收涨；康方生物、中国生物、京东健康、翰森制药等股均小幅收跌。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ ...

Core Insights - The pharmaceutical industry is experiencing a surge in innovative products, with clear domestic demand and significant potential for international expansion [4][14][25] - Investment opportunities are concentrated in innovative drugs and their supply chains, with a notable performance from CRO/CMO and chemical pharmaceuticals [9][15][17] - The report emphasizes the importance of innovation as the primary solution to industry challenges, driven by stable demand and supportive policies [26][32][41] Industry Overview - The pharmaceutical sector has faced revenue declines, with a 0.9% year-on-year decrease in revenue for the first three quarters of 2025, and net profit down by 2.2% [15][16] - The innovative drug sector has outperformed, with CRO/CMO and chemical pharmaceuticals showing net profit growth of 31.0% and 16.6% respectively [17][18] - The overall market is characterized by low fund holdings and historical valuation bottoms, indicating high investment value [20][25] Demand and Payment Dynamics - The demand for healthcare services is steadily increasing, with a projected 5% growth in total medical visits and hospital admissions in 2024 [26][28] - The aging population is expected to drive long-term demand, with 220 million people aged 65 and above by 2050 [28][30] - The medical insurance fund's income growth has outpaced expenditure growth, leading to a significant increase in fund reserves [32][36] Financing and Market Trends - The IPO market for healthcare has rebounded, with 28 IPOs in the first three quarters of 2025, a 100% increase from the previous year [42][43] - License-out transactions have surged, with transaction numbers increasing by 41% and total amounts reaching $92 billion, indicating a robust market for innovative drug licensing [48][50] - The number of IND applications and new clinical trials for innovative drugs has been steadily increasing, with a notable rise in NDA approvals [53][57] Technological Advancements - The report highlights the emergence of new technologies such as ADC and small nucleic acids, with domestic companies leading in these areas [60] - The focus on dual antibodies and GLP-1 drugs is expected to drive significant growth, with multiple development directions emerging [9][60] - The report notes that domestic companies are increasingly recognized for their innovative capabilities, particularly in the ADC space [60]

12月2日，中国企业药明生物与卡塔尔自由区管理局签署战略合作备忘录，双方将推动在生物药制造、 研发与创新领域的深度协作。卡塔尔商业与工业大臣费萨尔出席签约仪式。 ...

Core Viewpoint - The innovation drug sector in China is experiencing significant growth due to favorable policy developments, with the introduction of new drug listings in the national medical insurance catalog and commercial insurance, providing a stable policy outlook for innovative drug companies [1][2]. Group 1: Industry Trends - The China Hong Kong Stock Connect Innovation Drug Index increased by 0.30% as of December 11, 2025, with notable gains from companies such as Zhaoyan New Drug (+4.15%) and Rongchang Bio (+2.85%) [1]. - The national medical insurance catalog for 2025 successfully added 114 new drugs, including 50 innovative drugs, achieving a historical high success rate of 88% [1]. - The introduction of dual catalogs for medical insurance and commercial insurance is expected to directly benefit innovative drug companies, indicating a positive industry outlook [1]. Group 2: Market Opportunities - The top ten weighted stocks in the China Hong Kong Stock Connect Innovation Drug Index account for 72.68% of the index, highlighting the concentration of investment in leading innovative drug companies [2]. - The Harvest Innovation Drug ETF (520970) closely tracks the index, providing investors with access to leading companies involved in drug research, development, and production [2]. - Investors without stock accounts can leverage the Hong Kong Stock Connect Innovation Drug ETF linked fund (024700) to capitalize on the growth opportunities in the innovative drug sector [2].

Core Viewpoint - WuXi Biologics (02269) has shown a fluctuating upward trend in its stock price, currently at 33.74 HKD, up 0.42%, with a five-day volatility of 11.4%, indicating active market trading and some volatility [1] Group 1: Stock Performance - The biotechnology sector is experiencing a strong performance against the market trend, with several Chinese biotech stocks performing well despite the Hang Seng Index decline on December 10, 2025 [1] - Other related companies such as WuXi AppTec (02359) and China Biologic Products (01177) saw declines of 1.15% and 2.04%, respectively [1] - Notably, the stock of Gilead Sciences (01672) surged nearly 18% due to positive results from its obesity treatment drug research, but later dropped by 3.73% [1] Group 2: Technical Analysis - WuXi Biologics' stock price is currently near the 10-day moving average (approximately 32.03 HKD) and the 30-day moving average (approximately 33.17 HKD), slightly below the 60-day moving average (approximately 35.78 HKD) [1] - The Relative Strength Index (RSI) is at a neutral level of 52, with overall technical indicators signaling a "neutral" stance, while some trend indicators like MACD and Bollinger Bands are giving buy signals [1] - Key support levels are at 31.9 HKD and 31 HKD, while resistance levels are at 35.2 HKD and 36.1 HKD, with an overall upward probability of 54% [3] Group 3: Derivative Market Insights - The performance of derivative products has been notable, with leveraged characteristics highlighted in a volatile market [4] - On December 5, when WuXi Biologics' stock rose approximately 2.88%, related derivative products showed significant price changes, with UBS bull certificates (67145) rising 18% and JPMorgan bull certificates (66081) increasing by 14% [4] - This demonstrates that even moderate increases in the underlying stock can lead to amplified returns in derivatives due to leverage [4][5] Group 4: Investment Strategies - For investors considering derivatives, various products are available to meet different investment strategies and risk preferences [7] - UBS bull certificates (67145) have a strike price of 28.8 HKD and an actual leverage of about 5 times, providing a safety margin due to its distance from the current stock price [7] - For cautious investors, UBS bear certificates (58905) with a strike price of 40 HKD and an actual leverage of about 4.6 times may serve as a hedging option [7]

Key Points - The top three stocks with net inflows are Yingfu Fund (02800) with 2.602 billion, Hang Seng China Enterprises (02828) with 486 million, and Leap Motor (09863) with 395 million [1] - The top three stocks with net outflows are Tencent Holdings (00700) with -1.352 billion, SMIC (00981) with -463 million, and Horizon Robotics-W (09660) with -264 million [1] - In terms of net inflow ratio, Qingdao Bank (03866) leads with 75.11%, followed by Jiangsu Ninghu Expressway (00177) with 58.50%, and Far East Horizon (03360) with 54.75% [1] - The top three stocks with the highest net outflow ratios are Wisdom Hong Kong 100 (02825) at -100.00%, Shanghai Petrochemical (00338) at -61.38%, and Zhengzhou Bank (06196) at -55.42% [1] Net Inflow Rankings - Yingfu Fund (02800) had a net inflow of 2.602 billion, representing a 20.03% increase, closing at 26.140 (+0.77%) [2] - Hang Seng China Enterprises (02828) saw a net inflow of 486 million, with a 6.23% increase, closing at 93.340 (+1.02%) [2] - Leap Motor (09863) recorded a net inflow of 395 million, with a 53.79% increase, closing at 52.450 (-1.04%) [2] Net Outflow Rankings - Tencent Holdings (00700) experienced a net outflow of -1.352 billion, with a -14.49% decrease, closing at 612.000 (+0.16%) [2] - SMIC (00981) had a net outflow of -463 million, with a -13.37% decrease, closing at 69.800 (+3.87%) [2] - Horizon Robotics-W (09660) faced a net outflow of -264 million, with a -14.42% decrease, closing at 8.290 (+6.97%) [2] Net Inflow Ratio Rankings - Qingdao Bank (03866) had a net inflow ratio of 75.11%, with a net inflow of 4.4567 million, closing at 4.020 (+0.25%) [3] - Jiangsu Ninghu Expressway (00177) had a net inflow ratio of 58.50%, with a net inflow of 1.9164 million, closing at 10.060 (-0.89%) [3] - Far East Horizon (03360) had a net inflow ratio of 54.75%, with a net inflow of 3.6805 million, closing at 8.020 (+1.39%) [3]

Group 1 - Brazil's National Health Surveillance Agency (Anvisa) has officially approved the registration of the Butantan-DV single-dose dengue vaccine produced by the Butantan Institute [1] - The Brazilian government plans to provide the vaccine for free through the Brazilian Public Health System (SUS) starting in 2026 [1] - Butantan-DV is the world's first single-dose vaccine for dengue fever, developed in collaboration with China's WuXi Biologics under the coordination of the Brazilian Ministry of Health [1]

Group 1 - The number of initial jobless claims in the U.S. unexpectedly dropped to a three-year low, contrasting sharply with earlier weak ADP employment reports and record corporate layoffs, leading to a divergence in market perceptions regarding a soft landing for the U.S. economy [2] - The interest rate futures market is increasingly betting that the Federal Reserve will ignore data noise and implement rate cuts, indicating a significant shift in macroeconomic logic where investors believe the Fed's policy response has transitioned from being data-dependent to a more preemptive easing approach to mitigate potential economic slowdown risks [2] Group 2 - On Thursday, the Hong Kong Stock Connect saw a net inflow of HKD 1.5 billion, with the largest net inflow into the Tracker Fund of Hong Kong (02800.HK) amounting to HKD 2.61 billion, followed by WuXi Biologics (02269.HK) [2] - Conversely, Tencent Holdings (00700.HK) experienced the largest net outflow, totaling HKD 1.35 billion, followed by Semiconductor Manufacturing International Corporation (00981.HK) [2]